Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 1.00 |
| ▸ | PADI3 | Q9ULW8 | 2/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 1.00 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TGM2 | P21980 | 1/20 | 1.00 |
| ▸ | GALK1 | P51570 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptonigrin SCHEMBL29821157 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL3940 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL29371276 | 1.00 | MAPT (1.00) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25015126 | 0.93 | MAPT (0.87) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL30260509 | 0.93 | MAPT (0.87) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL23421492 | 0.92 | LMNA (0.85) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| Streptonigrin SCHEMBL6299739 | 0.91 | LMNA (0.84) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL23484220 | 0.89 | FNTA (0.82) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20257205 | 0.85 | SMN1; SMN2 (0.75) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29885591 | 0.82 | LMNA (0.70) | MAPTLMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| WO-2022025482-A1 | COMPOSITION FOR PREVENTING AND TREATING COLORECTAL CANCER, COMPRISING STREPTONIGRIN AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | 재단법인 아산사회복지재단 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | MYCBP, MYC, TERF2IP | MAPT 3232/4885LMNA 2253/4885SMN1; SMN2 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.